Starbucks, UPS and PepsiCo Pull Back on GLP-1 Weight-Loss Coverage as Large-Employer Coverage Falls From 72% to 60%, Leaving Workers Facing Hundreds of Dollars a Month Before an 8.2% Jump in 2027 Health Costs

The weight-loss drug boom has run into the corporate budget. With 2027 open enrollment under way, a growing list of large U.S. employers is scaling back or ending coverage of GLP-1 medications such as Wegovy and Zepbound when they are prescribed for weight loss. NBC News reported on Thursday that Starbucks, UPS, PepsiCo, Comcast, Mass General Brigham and the University of Louisville are among the organizations cutting or limiting the benefit, leaving workers who have relied on the drugs to decide whether to pay out of pocket, ration doses or stop treatment altogether.

The shift matters well beyond the pharmacy counter. GLP-1s have become one of the fastest-growing lines in employer health spending, and how companies handle them is turning into a test of how far employers will go to hold down premiums in a year when health costs are rising at their fastest pace in more than two decades.

The Numbers Behind the Pullback

Several separate surveys now point in the same direction:

  • Business Group on Health: According to the NBC report, the share of large employers in the group’s survey that cover GLP-1s for weight loss fell from 72% in 2025 to 60% in 2026, and none of the 127 employers surveyed planned to add the benefit. In an earlier survey of 105 members released this spring, nearly eight in 10 employers said GLP-1s were pushing up their health costs, and 10% of those covering the drugs said they likely would not continue in 2027.
  • WTW: As CNBC reported in late October, 53% of employers with more than 100 workers cover GLP-1s for weight loss, down from 57% in 2025 and the first decline in three years. Another 16% said they cover the drugs now but are considering dropping them, up from 9% a year earlier.
  • KFF: The 2026 Employer Health Benefits Survey found that 18% of firms with 200 or more workers cover GLP-1s mainly for weight loss, versus 19% last year. Among large firms that do not cover them, only 1% said they were very likely to start within a year, and 12% said they had stopped covering the drugs in the past 12 months.
  • Marsh: Per CNBC, Marsh expects health insurance cost per employee to rise 8.2% on average in 2027, the biggest increase since 2003, with GLP-1 use accounting for a full percentage point of that growth.

Why Employers Are Balking

The math is simple and unforgiving. CNBC reported that covering GLP-1s for weight loss typically costs employers in the mid-$500s to mid-$600s per user each month. Unlike many drugs, these are often taken long-term, and demand keeps climbing: CNBC, citing Gallup, said 11% of U.S. adults were taking a GLP-1 for weight loss in 2026, up from 3% in 2024.

At the same time, the payoff employers were hoping for has been slow to show up in their own data. Business Group on Health found that while more than half of covering employers expect significant clinical benefits, few have yet seen evidence such as lower obesity rates or fewer bariatric surgeries in their claims. Its members also expect an oral GLP-1 to increase overall demand, and only 9% anticipate prices falling.

Workers are already absorbing more of the bill elsewhere. KFF found that employees now contribute $7,471 a year on average toward family coverage, out of a total family premium of $28,303. For HR leaders, trimming a high-cost, fast-growing benefit can look easier than raising everyone’s payroll deductions again.

Not Everyone Is Cutting

Some companies are making the opposite bet. Bank of America CEO Brian Moynihan told CNBC in August that the bank spends about $250 million or more on GLP-1s, up from zero a few years ago, and called it a good investment because of the long-term health benefits for employees. That split shows there is no settled answer yet on whether these drugs eventually pay for themselves through fewer heart attacks, diabetes complications and sleep apnea cases.

The Middle Path: Direct-to-Consumer and Carve-Outs

Rather than an all-or-nothing choice, many employers are moving to alternatives. Drugmakers now sell directly to patients: CNBC reported self-pay starting prices of $149 a month for the Wegovy pill, $199 for the Wegovy shot and $299 for Zepbound, though Novo Nordisk has said its promotional prices could change in 2027. WTW found 8% of employers already steer workers to these direct programs and 28% are planning or considering it. Gallagher estimated 20% to 30% of its clients have dropped coverage for 2027 and are sending employees the direct route.

Other employers are reimbursing part of an employee’s out-of-pocket cost outside the pharmacy benefit manager, or paying for lifestyle and coaching programs from vendors such as Omada, Noom, Virta and CVS Weight Management. Marsh told CNBC those programs run roughly $65 to $100 per employee per month, or $150 or more if they include prescribing.

Why It Matters for Business Leaders

For employers, the GLP-1 decision is now a strategic one, not a line item. Dropping coverage can save money quickly, but it carries talent and health risks: doctors quoted by NBC warn of a two-tier system in which only workers who can afford several hundred dollars a month stay on treatment, and patients who stop often regain weight. In a tight labor market for skilled staff, a visible benefits cut can also hurt recruiting and retention.

For small and midsize businesses, the lesson is to look at the hybrid models larger companies are testing. Subsidizing direct-to-consumer purchases or funding a structured weight-management program may deliver much of the health value at a fraction of the cost of full pharmacy coverage. For investors, the trend is a reminder that GLP-1 demand increasingly depends on cash-pay and direct channels, not just insurance formularies, which puts pricing power and distribution at the center of the drugmakers’ growth story.

The Bottom Line

GLP-1s have gone from a perk employers rushed to add to one they are quietly rethinking. With health costs set for their steepest rise since 2003, more companies will try to split the difference between empathy and economics in 2027, and the outcome will shape both workers’ health and the next phase of the weight-loss drug market.

Benefits questions pile up every open-enrollment season. MAJ.COM Voice AI gives HR teams, clinics and benefits brokers 24/7 AI voice agents that answer every inbound call, handle outbound follow-ups and support members around the clock, so no employee question or new lead goes unanswered. Learn more about MAJ.COM Voice AI.

Edited by Coron @QUE.COM
Website: https://QUE.COM Intelligence
Sponsored by: https://MAJ.COM AI Autonomous


Discover more from QUE.com

Subscribe to get the latest posts sent to your email.

Coron @QUE.COM

Editor at QUE.com Intelligence.

coronquecom has 201 posts and counting.See all posts by coronquecom

Leave a Reply

Connect with

Discover more from QUE.com

Subscribe now to keep reading and get access to the full archive.

Continue reading